[Prevention of sudden death after myocardial infarction: should the "MADIT" strategy be generally applied? Arguments
1Unidad de Arritmias, Hospital General Gregorio Marañón, Madrid.
Revista Espanola De Cardiologia
|July 1, 1997
Insights
The Multicenter Automatic Defibrillator Implantation Trial (MADIT) found implantable cardioverter defibrillators improved survival in high-risk patients. However, more data is needed on antiarrhythmic drug efficacy and safety.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Context:
- The Multicenter Automatic Defibrillator Implantation Trial (MADIT) evaluated treatments for patients with prior myocardial infarction, asymptomatic unsustained ventricular tachycardia, and reduced left ventricular function.
- This patient group faces a significant risk of sudden cardiac death.
Purpose:
- To compare the efficacy and safety of implantable cardioverter defibrillators (ICDs) versus conventional antiarrhythmic drug treatment in high-risk cardiac patients.
- To assess the impact of ICDs on survival rates in this specific population.
Summary:
- The MADIT trial indicated that patients receiving an implantable cardioverter defibrillator (ICD) experienced better survival rates compared to those treated with antiarrhythmic drugs.
- This benefit was observed in individuals with a history of myocardial infarction, asymptomatic unsustained ventricular tachycardia, and impaired left ventricular function.
Impact:
- The findings support the use of ICDs as a life-saving intervention for selected patients at high risk of ventricular arrhythmias.
- Further research is necessary to fully understand the efficacy and safety profile of conventional antiarrhythmic treatments in this context, which currently limits broader clinical applicability.
Abstract:
The Multicenter Automatic Defibrillator Implantation Trial (MADIT) suggests that survival in patients with prior myocardial infarction, asymptomatic unsustained ventricular tachycardia and reduced left ventricular function was better among the patients who received implantable cardioverter defibrillator than that in the drug-treatment group. Nevertheless the absence of data about the efficacy and security of the conventional antiarrhythmic treatment weakness its result and clinical applicability.
More Related Videos
Related Concept Videos
01:17Ischemic Heart Disease: Overview
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:26Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...